Navigation Links
Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Society's Annual Meeting
Date:5/7/2008

NEW BRUNSWICK, N.J., May 7 /PRNewswire-FirstCall/ -- Johnson & Johnson will provide a pre-recorded webcast for financial analysts on Friday, May 9 at 4:00 p.m. (Eastern Time) to coincide with the American Pain Society's (APS) annual meeting in Tampa, Fla. Phase 3 clinical data presentations on investigational tapentadol immediate release (IR), a novel centrally acting oral analgesic, will be presented for the first time at APS.

A pre-recorded Webcast, with the lead tapentadol researchers, will be made available concurrent to the data presentations being made during the poster session at APS. Pre-registration is not required to view the webcast/podcast.

The presentation will provide an overview on tapentadol IR and review data from the following clinical posters:
-- Efficacy of Tapentadol Immediate Release in Patients With Pain After

Bunionectomy

-- Analgesic Efficacy of Tapentadol Immediate Release in Patients With

Pain From End-Stage Joint Disease

-- Tapentadol Immediate Release is Associated With Improved

Gastrointestinal Tolerability Compared With Oxycodone Immediate Release

Over 90 Days in Patients With Lower Back or Osteoarthritis Pain

The webcast/podcast and replay can be accessed by clicking on "Webcasts/Presentations" in the Investor Relations section of the Company's website at http://www.jnj.com.


'/>"/>
SOURCE Johnson & Johnson
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine technology :

1. Steroids Provide No Survival Benefit for Children With Bacterial Meningitis
2. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
3. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
4. Gene Therapy Provides Vision to People who Were Nearly Blind
5. Arpida Provides Further Comments on the Pivotal Phase III Trials
6. Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans
7. Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
8. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
9. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
10. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
11. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2008)...iland, May 9 /PRNewswire-USNewswire/ -- An emergen...Protection of Animals (WSPA),is on stand-by in Tha...yanmar to assess and then relieve the suffering of...on for food and their livelihoods., WSPA is rec...,Organization of the United Nations (FAO) while pr...
(Date:5/9/2008)...ay 9 /- Ardea Biosciences, ...scovery and development of,small- molecule therape...atory diseases, including gout, today announced th...sident, Finance and Operations and Chief,Financial...om our board of,directors shortly thereafter. The ...
(Date:5/8/2008)... /- Globus Medical, Inc., the largest... world and a recognized,leader in motion preservat...enrollment in its SECURE(R)-C Cervical Artificial ... to mimic the normal motion of the spine in,order ...native to fusion in,the treatment of symptomatic c...
(Date:5/8/2008)...ll., May 8 /- Siemens Healt...dings (LabCorp(R)) today announced,that they have ...e,possibilities to co-develop new clinical diagnos...etabolic syndrome, oncology and diabetes. Under th...eloping new tests that,could make the biggest impa...
Breaking Medicine Technology:Animals That Cyclone Survivors Depend on Need Help Now 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4Canola Oil Can Help Americans Meet Dietary Fat Recommendations 2898 1Canola Oil Can Help Americans Meet Dietary Fat Recommendations 2898 2Brown researchers make major signal transduction discovery 2897 1Brown researchers make major signal transduction discovery 2897 2Diet com Enters Strategic Collaboration To Support Microsoft HealthVault 2894 1Diet com Enters Strategic Collaboration To Support Microsoft HealthVault 2894 2Genta to Present at Bio Investor Forum 2007 Conference 2889 1Genta to Present at Bio Investor Forum 2007 Conference 2889 2Genta to Present at Bio Investor Forum 2007 Conference 2889 3
...nt duloxetine, at,a once-daily dose of 60 mg, sign...symptoms associated with depression in a new,eigh...ents with at,least moderate pain and major depress...European Congress of Psychiatry (AEP),in Madrid, S...ommonly referred to as,serotonin and norepinephrin...
...rstCall/ --,Alfacell Corporation,s ONCONASE (ranpi...oad in antibody conjugates for cancer therapy,acc...erapeutic,Antibodies. , In a chapter of the text t...marizes preclinical research indicating that the,s...umber of tumor,models, including non-Hodgkin,s lym...
Other Medicine Technology:In New Study, Duloxetine Reduced Non-specific Pain and Emotional,Symptoms Associated with Depression 2In New Study, Duloxetine Reduced Non-specific Pain and Emotional,Symptoms Associated with Depression 3In New Study, Duloxetine Reduced Non-specific Pain and Emotional,Symptoms Associated with Depression 4In New Study, Duloxetine Reduced Non-specific Pain and Emotional,Symptoms Associated with Depression 5In New Study, Duloxetine Reduced Non-specific Pain and Emotional,Symptoms Associated with Depression 6Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 2Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 3Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 4
(Date:5/12/2008)...-- NutraCea (OTC Bulletin Board:,NTRZ), a world le...rch and,technology, today announced financial resu...nsolidated net revenues rose 155% to $5.1 million ...dated net revenues of $2.0,million for the first q...arily due to a $860,000 increase in sales of produ...
(Date:5/12/2008)...niversity of Michigan Comprehensive Cancer Center ... patients are more likely to survive cancers of th...y, they found that cancers linked to HPV, or human...t chemotherapy and radiation treatments, while tum...actor receptor are the least responsive and most d...
(Date:5/12/2008)...e-FirstCall/ -- China Yingxia,International, Inc. ...e,Company"), a leading provider in the nutraceutic...e and distribution of organic nutritional food,pro...the People,s Republic,of China ("PRC"), announced ...ay 16, 2008, at 10:00 a.m. EDT, to discuss the Com...
(Date:5/12/2008)..., Montreal, May 12, 2008 A team of researchers ...enafil protects the heart in mice with Duchenne mu...ine Des Rosiers from the Universit de Montral and ...h Dr. Basil Petrof of the Research Institute of th...hristian Deschepper of the Institut de recherches ...
Breaking Medicine News(10 mins):Health News:NutraCea Announces First Quarter 2008 Financial Results 2Health News:NutraCea Announces First Quarter 2008 Financial Results 3Health News:NutraCea Announces First Quarter 2008 Financial Results 4Health News:NutraCea Announces First Quarter 2008 Financial Results 5Health News:NutraCea Announces First Quarter 2008 Financial Results 6Health News:HPV linked to better survival in tonsil, tongue cancer, U-M study finds 2Health News:HPV linked to better survival in tonsil, tongue cancer, U-M study finds 3Health News:China Yingxia International, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:New approach to protect the hearts of patients with muscular dystrophy 2Health News:New approach to protect the hearts of patients with muscular dystrophy 3
...educe the bio-terrorism threat of the Venezuelan e...rs at the University of Texas Medical Branch at Ga... step in the development of effective drug therapi...tis (VEE) virus, which is a potential bio-terroris...
...a safe way to monitor the fate of transplanted pan...issue of the journal Diabetes. // Researchers from...sachusetts General Hospital (MGH) said that they w...g the guidelines laid down for human transplants. ...
...ported from Rajasthan, officials say. According to...als are treating// 20 patients with symptoms of de...the maximum number of cases have been reported fro...i Madhopur districts. With dengue spreading its ...
...int task force of the American College of Chest Ph.../ and Environmental Medicine (ACOEM), and the Nati...onsistent approach to the screening and management...l motor vehicle (CMV) operators. Published as a su...
Other Medicine News:Health News:A New drug Developed To Fight The Bio-Terrorism Threat Of VEE Virus 2Health News:MRI Can Monitor Transplanted Islets 2Health News:Updated Sleep Apnea Screening Recommended for Commercial Drivers 2Health News:Updated Sleep Apnea Screening Recommended for Commercial Drivers 3Health News:Updated Sleep Apnea Screening Recommended for Commercial Drivers 4
Bird and Cronin, Inc. is a leading manufacturer of Patient Footwear, Orthopedic Softgoods, and Specialty Patient Care Products. Our products are of the highest quality and available in the USA and In
Bird and Cronin, Inc. is a leading manufacturer of Patient Footwear, Orthopedic Softgoods, and Specialty Patient Care Products. Our products are of the highest quality and available in the USA and In
...s specifically designed to treat Achilles tendonit... aircells located under the foot arch and in back ...sion with every step to help reduce swelling and e...ight neoprene fabric and is simple to apply just ...
... choice to treat arthritic pain, carpal tunnel syn... cast removal. The durable canvas glove with adju... and compression to the wrist to help relieve swel...t prevents painful wrist flexion, and holds the wr...
Medicine Products: